Compare Stocks

→ These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALA Calithera Biosciences	$0.02 -33.3%	$0.02	$0.01 ▼ $0.50	$97K	-0.17	877 shs	191 shs
CWBR CohBar	$0.80	$0.82	$0.51 ▼ $6.90	$2.33M	1.54	1,006 shs	7 shs
DFFN Diffusion Pharmaceuticals		$4.64	$2.76 ▼ $7.40	$8.98M	1.78	10,937 shs	351,000 shs
LMNL Liminal BioSciences	$8.50 +0.1%	$8.47	$3.10 ▼ $8.50	$26.35M	1.03	63,470 shs	5,000 shs
NERV Minerva Neurosciences	$2.45 -2.8%	$3.34	$2.29 ▼ $13.49	$17.62M	0.21	17,522 shs	5,770 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALA Calithera Biosciences	-31.03%	-20.16%	0.00%	-33.33%	-52.61%
CWBR CohBar	0.00%	-11.14%	+5.21%	+3.15%	-54.29%
DFFN Diffusion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-22.60%
LMNL Liminal BioSciences	0.00%	0.00%	0.00%	0.00%	+27.44%
NERV Minerva Neurosciences	-2.78%	-2.39%	-4.67%	-69.90%	-5.77%

These AI trades triggered this morning (545% return) (Ad)

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CWBR CohBar	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	3.618 of 5 stars	3.0	5.0	0.0	4.6	1.8	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
CWBR CohBar	N/A	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	2.00	Hold	$11.00	348.98% Upside

Current Analyst Ratings

Latest CALA, NERV, CWBR, LMNL, and DFFN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/27/2024	NERV Minerva Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$11.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALA Calithera Biosciences	$9.75M	0.01	N/A	N/A	($0.40) per share	-0.05
CWBR CohBar	N/A	N/A	N/A	N/A	$5.27 per share	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	$6.97 per share	N/A
LMNL Liminal BioSciences	$310K	85.00	N/A	N/A	$8.97 per share	0.95
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.07) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CWBR CohBar	-$12.18M	-$4.36	N/A	∞	N/A	N/A	N/A	N/A	5/13/2024 (Estimated)
DFFN Diffusion Pharmaceuticals	-$15.59M	N/A	0.00	N/A	N/A	N/A	-69.96%	-62.98%	N/A
LMNL Liminal BioSciences	$380K	$0.29	29.31	∞	N/A	248.35%	-88.44%	-64.15%	N/A
NERV Minerva Neurosciences	-$30M	-$4.65	N/A	N/A	N/A	N/A	N/A	-50.27%	5/20/2024 (Estimated)

Latest CALA, NERV, CWBR, LMNL, and DFFN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/22/2024	Q4 2023	NERV Minerva Neurosciences	-$0.88	-$1.19	-$0.31	-$1.19	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
CWBR CohBar	N/A	N/A	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALA Calithera Biosciences	N/A	N/A	N/A
CWBR CohBar	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	10.71	10.71
LMNL Liminal BioSciences	0.02	2.78	2.78
NERV Minerva Neurosciences	N/A	12.57	12.58

Ownership

Institutional Ownership

Company	Institutional Ownership
CALA Calithera Biosciences	N/A
CWBR CohBar	2.47%
DFFN Diffusion Pharmaceuticals	9.95%
LMNL Liminal BioSciences	0.66%
NERV Minerva Neurosciences	34.56%

Insider Ownership

Company	Insider Ownership
CALA Calithera Biosciences	6.60%
CWBR CohBar	6.51%
DFFN Diffusion Pharmaceuticals	1.80%
LMNL Liminal BioSciences	2.20%
NERV Minerva Neurosciences	6.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
CWBR CohBar	9	2.91 million	2.72 million	Not Optionable
DFFN Diffusion Pharmaceuticals	13	2.04 million	2.00 million	Not Optionable
LMNL Liminal BioSciences	251	3.10 million	3.04 million	Not Optionable
NERV Minerva Neurosciences	9	6.99 million	6.55 million	Not Optionable

CALA, NERV, CWBR, LMNL, and DFFN Headlines

Source	Headline
	West Branch overcomes slow start to get by Minerva wkbn.com - April 20 at 10:08 AM
	Police: 3 injured in Minerva Park single-vehicle crash msn.com - April 20 at 10:08 AM
	Off-duty firefighters & neighbor rescue baby, residents from burning Minerva house msn.com - April 20 at 10:08 AM
	Minerva Neurosciences (NASDAQ:NERV) Stock Crosses Below 200 Day Moving Average of $5.57 americanbankingnews.com - April 20 at 3:34 AM
	Crestwood softball doomed by defensive miscues in loss to Minerva weeklyvillager.com - April 4 at 8:40 PM
	Prairie voles display signs of human-like depression, show promise as animal model msn.com - April 4 at 8:40 PM
	Andreas Martinos firm Minerva Marine sells aframax tanker after newbuilding orders tradewindsnews.com - April 4 at 7:34 AM
	Here Comes Rutgers Day rutgers.edu - April 1 at 10:14 AM
	New track and field season gives Minerva sprinter Kyleigh Lippincott a fresh start msn.com - March 31 at 2:50 AM
	Irish singer/songwriter Enda Reilly to perform in Minerva on April 12 reviewonline.com - March 28 at 9:43 PM
	Reuben Norman litter picking at Minerva Primary School somersetcountygazette.co.uk - March 28 at 9:43 PM
	F\|T: The FinTech Times – Minerva chases anti-money laundering big leagues betakit.com - March 18 at 7:55 PM
	BMS completes $14bn takeover of Karuna pharmaphorum.com - March 18 at 7:55 PM
	Minerva Porras, 86 riverheadlocal.com - March 17 at 12:39 PM
	Social factors taskforce launches guidance with support from Minerva manifest.co.uk - March 15 at 1:01 PM
	Potts Point homelessness encampment moved on from Minerva-Metro Theatre site msn.com - March 14 at 9:56 PM
	Minerva Named "One to Watch" in Chartis Financial Crime and Compliance 50 Rankings tmcnet.com - March 14 at 9:56 PM
	Renovated Manti Temple, preserved Minerva Teichert murals ready for 3-week public open house msn.com - March 13 at 10:46 PM
	Potts Point homelessness encampment moved on by Minerva-Metro Theatre developer owners news.com.au - March 13 at 10:46 PM
	Minerva Named Top AI & Data Product in the 2024 Product Awards tmcnet.com - March 13 at 12:45 PM
	Acadia pulls trials of pimavanserin after schizophrenia fail pharmaphorum.com - March 12 at 8:51 AM
	FDA Delays Approval of Roluperidone for Schizophrenia Treatment medindia.net - February 29 at 3:38 PM
	FDA Denies Approval of Roluperidone for Negative Symptoms of Schizophrenia empr.com - February 28 at 6:41 PM
	Minerva slumps as FDA finds fault with schizophrenia filing pharmaphorum.com - February 28 at 8:40 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

CohBar

NASDAQ:CWBR

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

Diffusion Pharmaceuticals

NASDAQ:DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Liminal BioSciences

NASDAQ:LMNL

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Minerva Neurosciences

NASDAQ:NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial